HIỆU LỰC VÀ TÍNH AN TOÀN CỦA PYRONARIDINE-ARTESUNATE TRONG ĐIỀU TRỊ BỆNH NHÂN SỐT RÉT PLASMODIUM FALCIPARUM KHÔNG BIẾN CHỨNG TẠI GIA LAI, NĂM 2021-2023

Abstract

Background: According to the recommendation of the World Health Organization, if the treatment effectiveness of an antimalarial drug is below 90%, it is necessary to replace it with another drug with higher effectiveness. Pyronaridine-Artesunate is being used to treat patients with malaria, so monitoring to evaluate the effectiveness of this antimalarial drug is necessary and should be done regularly. Objectives: To evaluate the efficacy and safety of PyronaridineArtesunate for treatment of uncomplicated P. falciparum malaria patients in Gia Lai from 2021 to 2023. Materials and methods: A clinical trial study, label Open, uncontrolled by the WHO method- in vivo 42 days. Total 75 patients infected with P. falciparum in Gia Lai were enrolled from March 2021 to December 2023. Results: The rate of patients infected with P. falciparum with complete clinical and parasitological responsed not corrected by PCR after day 42 was 97.1%, the rate of late treatment failure was 2.9%. 50% parasite clearance time was 9.61 hours, higher than the WHO recommendation of 5.2 hour. The rate of patients with remaining parasites on day 3 was 54.8% (23/42) in 2021 and 50.0% (16/32) in 2023, respectively. Some malaria symptoms were recorded: headache, dizziness, loss of appetite. sleep, tired. Symptoms was resolve on their own after that do not require medical intervention. No side effects and no deaths were reported after taking the drug and during the study. Conclusion: The efficacy of Pyronaridine-Artesunate against P. falciparum is still high over 90% (97.1%), Pyronaridine-Artesunate is safe for patients.